Supernus Announces Paragraph IV ANDA Filing for XADAGO®
04 mai 2021 20h49 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Host First Quarter 2021 Financial Results Conference Call
27 avr. 2021 17h44 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
02 avr. 2021 16h58 HE
|
Supernus Pharmaceuticals, Inc.
Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade Supernus plans to make Qelbree available in the U.S. in 2Q 2021 ROCKVILLE, Md.,...
Supernus to Present at Cowen Healthcare Conference
26 févr. 2021 09h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
25 févr. 2021 16h00 HE
|
Supernus Pharmaceuticals, Inc.
Full year 2020 total revenues of $520.4 million, a 32% increase compared to 2019Full year 2020 operating earnings of $173.7 million, a 17% increase compared to 2019SPN-812 NDA assigned an early April...
Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call
23 févr. 2021 09h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA
22 févr. 2021 08h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients
08 févr. 2021 09h00 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference
06 janv. 2021 17h29 HE
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD
22 déc. 2020 18h07 HE
|
Supernus Pharmaceuticals, Inc.
Met primary endpoint with robust statistical significanceShowed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical significanceShowed statistically significant onset...